Minimal Residual Disease Detection in Acute Leukemia Patients by Flow Cytometric Assay of Cross-lineage Antigen Expression
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : It has been demonstrated that flow cytometric detection of minimal residual disease (MRD) has a prognostic significance in the treatment of patients with acute leukemia. We investigated the significance of flow cytometric MRD detection for the first time in Korea. Methods : We analyzed the results of MRD detection in morphologically complete remission bone marrow aspirates from 89 patients with newly-diagnosed or relapsed acute leukemia, in which leukemic cells had cross-lineage antigen expression. Patients were grouped based on MRD frequencies:≥1.0%, high MRD; <1.0%, low MRD. Results : Forty-seven ALL patients consisted of 10 with high and 37 with low MRD levels. Patients with high MRD levels showed a tendency of more frequent relapse than those with low MRD levels (40.0% and 13.5%, respectively) (P=0.08). High MRD group showed a tendency of short relapsefree survival (RFS) and overall survival (OS), although the differences were not statistically significant. Forty-two AML patients consisted of 16 with high and 26 with low MRD levels. There were no correlations between the MRD levels and relapse rate, RFS or OS. AML patients with high MRD levels showed significantly higher rate of unfavorable cytogenetic risk categories and lower rate of favorable risk categories (P=0.03). Conclusions : MRD detection by flow cytometric assay of cross-lineage antigen expression would be useful in predicting treatment outcome in patients with ALL rather than AML. We expect that the establishment of the standardization of methods, time to test or antibody combination would be achieved through further trials in this country. (Korean J Lab Med 2010;30:533-9)
Abstract
Background : It has been demonstrated that flow cytometric detection of minimal residual disease (MRD) has a prognostic significance in the treatment of patients with acute leukemia. We investigated the significance of flow cytometric MRD detection for the first time in Korea. Methods : We analyzed the results of MRD detection in morphologically complete remission bone marrow aspirates from 89 patients with newly-diagnosed or relapsed acute leukemia, in which leukemic cells had cross-lineage antigen expression. Patients were grouped based on MRD frequencies:≥1.0%, high MRD; <1.0%, low MRD. Results : Forty-seven ALL patients consisted of 10 with high and 37 with low MRD levels. Patients with high MRD levels showed a tendency of more frequent relapse than those with low MRD levels (40.0% and 13.5%, respectively) (P=0.08). High MRD group showed a tendency of short relapsefree survival (RFS) and overall survival (OS), although the differences were not statistically significant. Forty-two AML patients consisted of 16 with high and 26 with low MRD levels. There were no correlations between the MRD levels and relapse rate, RFS or OS. AML patients with high MRD levels showed significantly higher rate of unfavorable cytogenetic risk categories and lower rate of favorable risk categories (P=0.03). Conclusions : MRD detection by flow cytometric assay of cross-lineage antigen expression would be useful in predicting treatment outcome in patients with ALL rather than AML. We expect that the establishment of the standardization of methods, time to test or antibody combination would be achieved through further trials in this country. (Korean J Lab Med 2010;30:533-9)
참고문헌 (25)
- Vidriales MB, "Minimal residual disease monitoring by flow cytometry", Best Pract Res Clin Haematol, 16, pp.599~612 (2003)
- Chung NG, "The detection and significance of minimal residual disease in acute and chronic leukemia", Tissue Antigens, 68, pp.371~385 (2006)
- Kern W, "Monitoring of minimal residual disease in acute myeloid leukemia", Cancer, 112, pp.4~16 (2008)
- Campana D, "Status of minimal residual disease testing in childhood haematological malignancies", Br J Haematol, 143, pp.481~489 (2008)
- Al-Mawali A, "The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia", Am J Clin Pathol, 131, pp.16~26 (2009)
- Ciudad J, "Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia", J Clin Oncol, 16, pp.3774~3781 (1998)
- Coustan-Smith E, "Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia", Blood, 96, pp.2691~2696 (2000)
- Coustan-Smith E, "Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lym phoblastic leukemia", Blood, 100, pp.52~58 (2002)
- Dworzak MN, "Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia", Blood, 99, pp.1952~1958 (2002)
- Coustan-Smith E, "Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse", Leukemia, 18, pp.499~504 (2004)
- Coustan-Smith E, "A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome", Blood, 108, pp.97~102 (2006)
- Borowitz MJ, "Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study", Blood, 111, pp.5477~5485 (2008)
- San Miguel JF, "Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients", Blood, 90, pp.2465~2470 (1997)
- Venditti A, "Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia", Blood, 96, pp.3948~3952 (2000)
- Plata E, "Flowcytometric detection of minimal residual disease with atypical antigen combinations in patients with de novo acute myeloid leukemia", Ann Hematol, 79, pp.543~546 (2000)
- San Miguel JF, "Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification", Blood, 98, pp.1746~1751 (2001)
- Venditti A, "Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia", J Hematother Stem Cell Res, 11, pp.349~357 (2002)
- Coustan-Smith E, "Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia", Br J Haematol, 123, pp.243~252 (2003)
- Kern W, "Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia", Blood, 104, pp.3078~3085 (2004)
- Kern W, "Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia", Haematologica, 89, pp.528~540 (2004)
- Feller N, "MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia", Leukemia, 18, pp.1380~1390 (2004)
- Buccisano F, "The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia", Leukemia, 20, pp.1783~1789 (2006)
- 신소영, "급성백혈병 완전 관해 골수에서 항원형 이상 세포의 분포", The Korean Journal of Laboratory Medicine, 28(1), pp.1~7 (2008), 대한진단검사의학회
- Kern W, "Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow", Haematologica, 88, pp.646~653 (2003)
- Mrozek K, "Cytogenetics in acute leukemia", Blood Rev, 18, pp.115~136 (2004)